Drug Channels: IRA Fallout is Changing the Medicare Access Landscape

The Inflation Reduction Act (IRA) promised major wins for patients. In many ways, it’s delivering. But CareMetx's latest analysis reveals how those benefits are triggering disruptive ripple effects, creating new access barriers and strategic hurdles for manufacturers in 2025.

In a recent Drug Channels article, Scott Hughes, Vice President of Strategy at CareMetx, breaks down how these changes are unfolding across three key therapeutic areas: immunology, oncology, and endocrinology. Based on a detailed analysis of 2025 Medicare Advantage (MAPD) and Part D (PDP) plan data, the article explores how drug coverage decisions are tightening, prior authorization (PA) requirements are rising, and out-of-pocket costs are climbing, even in categories with historically stable access. To view all data, download The IRA Disruption Report: A Strategic Look at Patient Access Changes.

In immunology, some therapies lost coverage for as many as 15 million beneficiaries, while others saw a surge in new PA requirements. Oncology drugs faced similar disruptions, with cost-sharing increases affecting nearly 3 million lives. And in endocrinology, where patients rely on consistent, ongoing care, coverage losses and escalating costs are making chronic disease management even more complex.

These shifts carry significant implications for patient access and manufacturer strategy alike. As Scott notes, “Manufacturers will need to account for more variability, more complexity, and more plan-by-plan nuances.”

Read the full post on Drug Channels here.